PRXL2B

Summary

PRXL2B (peroxiredoxin like 2B, HGNC:28390) is a protein-coding gene on chromosome 1p36.32, encoding Prostamide/prostaglandin F synthase (Q8TBF2). Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor.

Predicted to enable prostaglandin F synthase activity and thioredoxin peroxidase activity. Predicted to be involved in prostaglandin biosynthetic process. Located in extracellular exosome and mitochondrion.

Source: NCBI Gene 127281 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 62 total
• MANE Select transcript: NM_152371

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28390
Approved symbol	PRXL2B
Name	peroxiredoxin like 2B
Location	1p36.32
Locus type	gene with protein product
Status	Approved
Aliases	MGC26818
Ensembl gene	ENSG00000157870
Ensembl biotype	protein_coding
OMIM	621349
Entrez	127281

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 14 protein_coding, 5 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000378424, ENST00000378425, ENST00000378427, ENST00000419916, ENST00000444521, ENST00000464043, ENST00000465233, ENST00000474659, ENST00000476686, ENST00000477045, ENST00000481683, ENST00000484099, ENST00000493183, ENST00000498083, ENST00000537325, ENST00000877697, ENST00000877698, ENST00000877699, ENST00000923153, ENST00000923154, ENST00000971684

RefSeq mRNA: 6 — MANE Select: NM_152371 NM_001195736, NM_001195737, NM_001195738, NM_001195740, NM_001195741, NM_152371

CCDS: CCDS44, CCDS55564, CCDS90843

Canonical transcript exons

ENST00000419916 — 7 exons

Exon	Start	End
ENSE00002252442	2586777	2586948
ENSE00003485678	2589410	2591468
ENSE00003533718	2587741	2587792
ENSE00003535204	2588922	2589040
ENSE00003566896	2588550	2588625
ENSE00003620374	2587091	2587295
ENSE00003630848	2588390	2588453

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 94.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.1062 / max 59.5857, expressed in 1681 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
266	3.8187	1459
267	3.1072	1377
265	0.1803	84

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	94.55	gold quality
anterior cingulate cortex	UBERON:0009835	93.39	gold quality
right frontal lobe	UBERON:0002810	92.35	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.25	gold quality
frontal cortex	UBERON:0001870	92.23	gold quality
prefrontal cortex	UBERON:0000451	92.18	gold quality
cerebral cortex	UBERON:0000956	92.03	gold quality
superior frontal gyrus	UBERON:0002661	91.83	gold quality
duodenum	UBERON:0002114	91.79	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.61	gold quality
hypothalamus	UBERON:0001898	91.43	gold quality
temporal lobe	UBERON:0001871	91.33	gold quality
amygdala	UBERON:0001876	91.29	gold quality
Ammon’s horn	UBERON:0001954	91.19	gold quality
nucleus accumbens	UBERON:0001882	90.45	gold quality
transverse colon	UBERON:0001157	90.24	gold quality
right uterine tube	UBERON:0001302	90.15	gold quality
brain	UBERON:0000955	88.96	gold quality
substantia nigra	UBERON:0002038	88.81	gold quality
primary visual cortex	UBERON:0002436	88.61	gold quality
putamen	UBERON:0001874	88.60	gold quality
ventricular zone	UBERON:0003053	88.55	gold quality
caudate nucleus	UBERON:0001873	88.27	gold quality
small intestine	UBERON:0002108	88.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	88.08	gold quality
right adrenal gland cortex	UBERON:0035827	88.02	gold quality
left adrenal gland cortex	UBERON:0035825	87.34	gold quality
right adrenal gland	UBERON:0001233	87.14	gold quality
intestine	UBERON:0000160	87.11	gold quality
colon	UBERON:0001155	87.08	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-4850	no	217.28
E-ANND-3	no	1.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

53 targeting PRXL2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-422A	99.18	65.83	550
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-1228-3P	99.00	66.53	857
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-378A-3P	98.43	66.10	548
HSA-MIR-378C	98.43	66.10	548
HSA-MIR-378D	98.43	66.10	548

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prxl2b	ENSMUSG00000029059
rattus_norvegicus	Prxl2b	ENSRNOG00000085951

Protein

Protein identifiers

Prostamide/prostaglandin F synthase — Q8TBF2 (reviewed: Q8TBF2)

Alternative names: Peroxiredoxin-like 2B, Protein FAM213B

All UniProt accessions (6): A0A0A0MRV4, A0A0A0MT35, A0A2P0CTH9, J3KRV9, J3QKK8, Q8TBF2

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha).

Subcellular location. Cytoplasm. Cytosol.

Similarity. Belongs to the peroxiredoxin-like PRXL2 family. Prostamide/prostaglandin F synthase subfamily.

Isoforms (6)

UniProt ID	Names	Canonical?
Q8TBF2-1	1	yes
Q8TBF2-2	2
Q8TBF2-3	3
Q8TBF2-4	4
Q8TBF2-6	5
Q8TBF2-7	6

RefSeq proteins (6): NP_001182665, NP_001182666, NP_001182667, NP_001182669, NP_001182670, NP_689584* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR032801	PXL2A/B/C	Family
IPR036249	Thioredoxin-like_sf	Homologous_superfamily

Pfam: PF13911

Catalyzed reactions (Rhea), 2 shown:

• prostamide F2alpha + [thioredoxin]-disulfide = prostamide H2 + [thioredoxin]-dithiol (RHEA:26373)
• prostaglandin H2 + [thioredoxin]-dithiol = prostaglandin F2alpha + [thioredoxin]-disulfide (RHEA:28214)

UniProt features (6 total): splice variant 4, chain 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9USA	X-RAY DIFFRACTION	2.3
9US9	X-RAY DIFFRACTION	3.38

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TBF2-F1	92.52	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 108

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2162123	Synthesis of Prostaglandins (PG) and Thromboxanes (TX)

MSigDB gene sets: 121 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, GOBP_FATTY_ACID_BIOSYNTHETIC_PROCESS, LIAO_METASTASIS, GOBP_MONOCARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS, GOBP_UNSATURATED_FATTY_ACID_METABOLIC_PROCESS

GO Biological Process (6): prostaglandin biosynthetic process (GO:0001516), cyclooxygenase pathway (GO:0019371), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631), fatty acid biosynthetic process (GO:0006633), prostaglandin metabolic process (GO:0006693)

GO Molecular Function (5): oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616), prostaglandin H2 endoperoxidase reductase activity (GO:0036130), prostaglandin F synthase activity (GO:0047017), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (6): cytoplasm (GO:0005737), mitochondrion (GO:0005739), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), myelin sheath (GO:0043209), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Arachidonate metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	3
prostaglandin metabolic process	2
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	2
intracellular membrane-bounded organelle	2
prostanoid biosynthetic process	1
prostaglandin biosynthetic process	1
arachidonate metabolic process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
fatty acid metabolic process	1
lipid biosynthetic process	1
monocarboxylic acid biosynthetic process	1
prostanoid metabolic process	1
oxidoreductase activity, acting on CH-OH group of donors	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
endomembrane system	1
extracellular vesicle	1

Protein interactions and networks

STRING

426 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRXL2B	SUCLA2	Q9P2R7	535
PRXL2B	ERC1	Q8IUD2	532
PRXL2B	PRKG1	P14619	450
PRXL2B	POSTN	Q15063	433
PRXL2B	OAS2	P29728	401
PRXL2B	TNXB	P22105	401
PRXL2B	SHISAL2A	Q6UWV7	389
PRXL2B	VCF1	Q969W3	375
PRXL2B	PLAAT3	P53816	372
PRXL2B	TRIP12	Q14669	349
PRXL2B	ERICH6	Q7L0X2	332
PRXL2B	PTGES	O14684	330
PRXL2B	OR10C1	Q96KK4	327
PRXL2B	HACD2	Q6Y1H2	313
PRXL2B	HPGD	P15428	311
PRXL2B	ZNF414	Q96IQ9	311

IntAct

17 interactions, top by confidence:

A	B	Type	Score
PRXL2B	TCP11L1	psi-mi:“MI:0915”(physical association)	0.560
PRXL2B	COPS3	psi-mi:“MI:0915”(physical association)	0.560
PRXL2B	NARS1	psi-mi:“MI:0914”(association)	0.530
PRXL2B	PDPK1	psi-mi:“MI:0915”(physical association)	0.370
TNFSF11	PRXL2B	psi-mi:“MI:0915”(physical association)	0.370
WNT4	HLA-B	psi-mi:“MI:0914”(association)	0.350
PRXL2B	COPS3	psi-mi:“MI:0915”(physical association)	0.000
PRXL2B	TCP11L1	psi-mi:“MI:0915”(physical association)	0.000
TCP11L1	PRXL2B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): NUCB1 (Affinity Capture-MS), HRAS (Affinity Capture-MS), NARS (Affinity Capture-MS), PROCR (Affinity Capture-MS), NUCB1 (Affinity Capture-MS), NARS (Affinity Capture-MS), BCAT1 (Affinity Capture-MS), HRAS (Affinity Capture-MS), FAM213B (Two-hybrid), TCP11L1 (Two-hybrid), FAM213B (Affinity Capture-MS), FAM213B (Affinity Capture-MS), NUCB1 (Affinity Capture-MS), NARS (Affinity Capture-MS), FAM213B (Affinity Capture-MS)

ESM2 similar proteins: A1A5C7, A5D7B1, A6H7A0, A6NCF5, A6QLN9, A8MUP2, D3YYU8, D3ZZ80, O43688, O75147, O88843, P08887, Q14CX5, Q3SZQ2, Q3UHH2, Q58CT4, Q5EA19, Q5R4Q7, Q5R7S9, Q5RCI5, Q5RFN0, Q5SP67, Q5SUV1, Q642A6, Q6IA17, Q6PCB0, Q7TPB4, Q86TI4, Q8BGR6, Q8BZI6, Q8K5A4, Q8N5I2, Q8N653, Q8R2Z5, Q8TBF2, Q8VE98, Q92737, Q969P0, Q96NJ5, Q96NT3

Diamond homologs: A0JPD7, A9CQL8, C1C416, D3ZVR7, Q3ZBK2, Q58CY6, Q5R7S9, Q5ZI34, Q641F0, Q6AXX6, Q6PBP3, Q8TBF2, Q9BRX8, Q9CYH2, Q9DB60, B5X9L9, Q28IJ3, Q6AZG8, Q6NV24, Q9ZUU2, Q7RTV5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	41
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1381 predictions. Top by Δscore:

Variant	Effect	Δscore
1:2586946:G:T	donor_gain	1.0000
1:2587293:G:GT	donor_gain	1.0000
1:2587739:A:AG	acceptor_gain	1.0000
1:2587740:G:GG	acceptor_gain	1.0000
1:2587740:GA:G	acceptor_gain	1.0000
1:2587776:GAGC:G	donor_gain	1.0000
1:2587790:GCG:G	donor_gain	1.0000
1:2587791:CGG:C	donor_loss	1.0000
1:2587793:G:GC	donor_loss	1.0000
1:2587793:G:GG	donor_gain	1.0000
1:2587794:T:A	donor_loss	1.0000
1:2588450:CAAG:C	donor_loss	1.0000
1:2588455:T:A	donor_loss	1.0000
1:2588952:A:AG	acceptor_gain	1.0000
1:2588953:G:GG	acceptor_gain	1.0000
1:2588953:GA:G	acceptor_gain	1.0000
1:2588953:GAA:G	acceptor_gain	1.0000
1:2588953:GAAGT:G	acceptor_gain	1.0000
1:2589037:TCAG:T	donor_loss	1.0000
1:2589038:CAG:C	donor_loss	1.0000
1:2589039:AGGT:A	donor_loss	1.0000
1:2589042:T:A	donor_loss	1.0000
1:2586946:G:GT	donor_gain	0.9900
1:2587292:GGAG:G	donor_gain	0.9900
1:2587293:G:T	donor_gain	0.9900
1:2587293:GAGGT:G	donor_loss	0.9900
1:2587295:GGT:G	donor_loss	0.9900
1:2587296:GTGC:G	donor_loss	0.9900
1:2587740:GAGC:G	acceptor_gain	0.9900
1:2587740:GAGCT:G	acceptor_gain	0.9900

AlphaMissense

1269 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:2587268:T:C	F81L	0.996
1:2587270:C:A	F81L	0.996
1:2587270:C:G	F81L	0.996
1:2587269:T:C	F81S	0.994
1:2587746:T:G	Y92D	0.991
1:2587786:T:C	F105S	0.990
1:2588419:C:A	A117D	0.990
1:2587236:G:A	G70D	0.986
1:2587112:T:A	W29R	0.985
1:2587112:T:C	W29R	0.985
1:2587269:T:G	F81C	0.985
1:2588617:T:A	V151D	0.985
1:2587179:C:A	A51D	0.984
1:2588602:G:A	G146E	0.984
1:2587155:G:A	G43E	0.983
1:2587169:C:A	R48S	0.983
1:2587170:G:C	R48P	0.983
1:2588584:G:A	G140E	0.983
1:2587148:C:A	R41S	0.982
1:2587151:T:C	F42L	0.982
1:2587153:C:A	F42L	0.982
1:2587153:C:G	F42L	0.982
1:2587167:G:A	C47Y	0.982
1:2588551:C:A	A129D	0.981
1:2588587:A:C	D141A	0.981
1:2588587:A:G	D141G	0.981
1:2587168:C:G	C47W	0.980
1:2587287:T:C	F87S	0.980
1:2588608:T:C	L148P	0.980
1:2587785:T:C	F105L	0.979

dbSNP variants (sampled 300 via entrez): RS1000675166 (1:2587319 C>G,T), RS1001255069 (1:2588461 C>CGGGTCA), RS1001658938 (1:2586250 G>A), RS1001817311 (1:2590762 C>A,T), RS1001866344 (1:2587513 G>A), RS1002055433 (1:2586351 G>A), RS1002331702 (1:2587629 G>A), RS1002681145 (1:2585385 G>A,C), RS1002751138 (1:2591217 C>T), RS1002812143 (1:2589636 G>A), RS1003120530 (1:2585137 T>C), RS1003273738 (1:2586458 C>G,T), RS1003919977 (1:2587637 GCAGAGGAA>G), RS1004725305 (1:2585611 C>A,T), RS1004891429 (1:2586794 C>A,T)

Disease associations

OMIM: gene MIM:621349 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000964_38	Ulcerative colitis	3.000000e-09
GCST004131_113	Inflammatory bowel disease	8.000000e-07
GCST004133_54	Ulcerative colitis	1.000000e-10
GCST005038_27	Allergic disease (asthma, hay fever or eczema)	3.000000e-08
GCST005523_1	Celiac disease	5.000000e-12
GCST005951_35	Body mass index	4.000000e-08
GCST009597_257	Multiple sclerosis	2.000000e-36

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases oxidation	3
Cyclosporine	decreases methylation, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Smoke	decreases expression, increases abundance	2
Particulate Matter	affects expression, decreases expression, increases abundance	2
GSK-J4	decreases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression, increases oxidation	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
clothianidin	decreases expression	1
jinfukang	increases expression	1
NSC 689534	affects binding, decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Pioglitazone	decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
Atrazine	decreases expression	1
Vehicle Emissions	affects expression, increases abundance	1
Hexachlorocyclohexane	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Cannabidiol	decreases expression	1
Copper	affects binding, decreases expression	1
Diazinon	decreases expression	1
Doxorubicin	decreases expression	1
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Dronabinol	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.